The S&P 500’s Top-Performing Sectors: 3 Lead the Pack…

Unsubscribe

Elon Warns “America Is Broke”. Trump’s Plan Inside. (From American Hartford Gold)The S&P 500’s Top-Performing Sectors: 3 Lead the Pack in 2025Written by Leo Miller on January 5, 2026 SummaryThe S&P 500 returned 18% in 2025, but only three sectors—technology, communications, and industrials—outperformed the index.AI adoption was the dominant driver of gains across all three sectors, from chipmakers and hyperscalers to defense firms and power infrastructure.Key stock contributors included NVIDIA, Broadcom, Alphabet, GE Aerospace, and Micron—all of which fueled sector-level outperformance.Despite notable volatility, the S&P 500 Index delivered an 18% total return in 2025—its third consecutive year of 15% or higher gains. However, the strength was not evenly distributed across all 11 sectors.Only three outperformed the broader index, driven by distinct tailwinds such as AI momentum, infrastructure investment, and content demand. Sector-level performance is based on State Street’s SPRD Sector ETFs.7 High-Yield Dividend Stocks You Need to See (Ad)7 High Yield Dividend Stocks to Buy Now 💰 Love steady payouts? This free report reveals 7 high-yield dividend stocks you need to know about. From Company #3, a tobacco giant innovating with smokeless products, to Company #4, famously known as “The Monthly Dividend Company,” these picks deliver steady income you can count on.Perfect for income-focused investors.Industrials Soar as Aerospace, Defense, and Power Drive GrowthComing in third place is the industrial sector, which slightly outperformed the index with a 19.5% return. Two key investment themes, aerospace and defense, as well as data centers, influenced the strong performance of this sector. GE Aerospace (NYSE: GE) and RTX (NYSE: RTX)delivered returns of 86% and 61%, respectively. Together, these gains contributed around 600 basis points to the sector’s total return.  Both firms saw strong sales growth from commercial and defense customers. GE Aerospace ended last quarter with a backlog of $175 billion, while the figure came in at $250 billion for RTX. These numbers are several times higher than the revenue GE and RTX generated over the last 12 months, providing significant revenue visibility going forward.Caterpillar (NYSE: CAT) delivered a return of 61%, benefiting greatly from data center buildouts. Caterpillar’s power generation business sells reciprocating engines. This machinery provides backup power to data centers in case electrical grids fail, and companies are increasingly using it to supply power in non-emergency situations.Hyperscalers and Mega-Merger Awards Communications Sector Second PlaceThe communications sector takes the silver medal in 2025, delivering a total return of 23%. Although often associated with the tech sector, Meta Platforms (NASDAQ: META) and Google parent company Alphabet (NASDAQ: GOOGL) are technically communications stocks. These names rose 13% and 66%, respectively, in 2025.Meta’s revenue growth accelerated in every quarter, driven by its investments in artificial intelligence (AI). The same was true for Google, with the company’s 16% revenue growth in Q3 2025 being its fastest in over three years. Google Search, Google Cloud, and YouTube ads all saw strong growth, driven by AI. Google also established itself as a leader in large language models through Gemini. These two stocks contributed 1,110 basis points to the sector’s return.Warner Bros. Discovery (NASDAQ: WBD) also played a key role, contributing more than 300 basis points of return. The stock surged 172% as multiple companies jockeyed for the right to acquire it, with WBD ultimately accepting Netflix’s (NASDAQ: NFLX) offer.5 Stocks That Could Double in 2026 (Ad)While everyone’s making predictions about what might happen in 2026, we’ve identified 5 stocks with catalysts that are already locked and loaded. These aren’t hopes or projections. These are scheduled events, signed contracts, and approved projects that will play out over the next 12 months. The difference between 100% gains and missing out completely? Positioning before 2026 arrives.Click here to get your free copy of this reportAI Pushes Tech to the Top of the HeapUnsurprisingly, technology took the cake for the best-performing sector in 2025, delivering a total return of 24.6%. AI drove gains across the sector. Advanced chip designers NVIDIA (NASDAQ: NVDA) and Broadcom (NASDAQ: AVGO) delivered returns of 39% and 51% as hyperscalers continued to demand more of their products. Together, these stocks contributed 760 basis points to the sector’s return.The memory chip trade also did some heavy lifting. Memory chip stock Micron Technology (NASDAQ: MU) soared 240%, and wafer fabrication equipment maker Lam Research (NASDAQ: LRCX) shot up 140%. Memory chips are experiencing a surge in demand due to the rise of AI. Micron has already sold its entire 2026 production capacity for high-bandwidth memory chips (HBM). This benefits Lam Research, as memory chip makers need to buy its equipment to increase production capacity. Combined, Micron and Lam contributed 380 basis points to the technology sector’s return.When it comes to AI applications, Palantir Technologies (NASDAQ: PLTR) is arguably the biggest winner in the sector. The stock rose 135%, with government and commercial customers in the United States spending billions to deploy its Artificial Intelligence Platform (AIP) software.AI Makes Its Mark Across Industrials, Communication, and TechnologyAI was the clear thread connecting all three of these sectors in 2025. From heavy machinery to software applications, the technology is making its presence felt throughout vast swaths of the economy.While analysts expect AI investment to continue rising in 2026, the winners in this space are likely to evolve, like the technology itself.Read this article online ›Featured StoriesThe AI Tech Paradox: Insiders Sell, the Case for Buying Gets StrongerThe AI stocks no one’s talking about (but institutions are quietly buying) (From TradingTips)Notable Newcomers: These 2025 IPOs Dominated the Year5 Stocks Under $5 (From TradingTips)Flu Season’s Here—This Dividend-Payer Controls the Shot Market3 Stocks Delivered +10% Buyback Yields in 2025—What’s Next in 2026?5 Stocks Retail Investors Are Betting on for 2026  Did you enjoy this article?

Thank you for subscribing to Insider Trades Daily, which covers the most recent insider buying and selling activity from Wall Street CEO’s, CFO’s, COO’s and other insiders. If you need help with your account, don’t hesitate to contact our South Dakota based support team at contact@marketbeat.com. If you no longer wish to receive email from InsiderTrades.com, you can unsubscribe. Copyright 2006-2026 MarketBeat Media, LLC. All rights reserved. 345 N Reid Pl., Suite 620, Sioux Falls, South Dakota 57103. United States of America..Link of the Day: Forget AI, This Will Be the Next Big Tech Breakthrough (From Brownstone Research)

This 100-Year-Old Indicator Just Flashed Red

You think the volatility is over?

Think again.

It may only be getting started.

According to a strange investment signal first documented just before the Great Depression, today’s market chaos may only be a preview of a much larger shift forming beneath the surface.

And if this historic pattern is right, what’s coming next could catch millions of investors off guard.

This signal has reappeared ahead of several major turning points over the last century. And today, it’s flashing the same warning again — pointing to a potential break in the market that could hit certain stocks much harder than others.

If this unfolding shift continues, many of America’s most popular companies could see deeper declines… especially those already showing early signs of weakness.

Most investors won’t recognize the danger until it’s too late.

But the real risk? Holding the wrong type of stocks into this next phase. Historically, this has been the moment when laggards fell further, faster.

That’s why our analysts have identified five stocks that may be especially vulnerable as this market shift plays out.

You’ll want to see this list immediately — and make sure you’re not accidentally exposed to any of these names.

Because if you are, taking action early may be one of the smartest defensive moves you can make this year.

To understand the shift underway…

And to see the five stocks analysts believe you should avoid right now…

Click here now — before the next move hits.

Sincerely,
Eliza Lasky
Weiss Advocate

---

Today’s Exclusive Content

FDA Approves Novo Nordisk’s Wegovy Pill: A Game Changer for 2026

Reported by Leo Miller. Article Posted: 12/31/2025. 

At a Glance

• Novo Nordisk shares have come under immense pressure in 2025, losing more than a third of their value.
• However, the company scored a huge win at the end of the year as U.S. regulators approved its weight-loss drug Wegovy in pill form.
• The new drug could help change NVO’s fortunes in 2026. However, Eli Lilly remains close on its tail.

After a year that has been anything but smooth sailing, pharmaceutical giant Novo Nordisk A/S (NYSE: NVO) is closing out 2025 on a brighter note. Shares jumped about 7% on Dec. 23 after the U.S. Food and Drug Administration (FDA) granted approval for Novo’s oral Wegovy weight-loss pill.

Despite that boost, Novo shares have delivered roughly a -40% total return in 2025 as of the Dec. 30 close. The FDA approval, however, could be a catalyst for stronger performance in 2026. Below we look back at the challenges Novo faced in 2025 and update the outlook for NVO stock.

Q3 2025 Shows How Fast the Growth Narrative Changed

Best $19 you’ll spend this year. (Ad)

A former hedge fund manager known for cutting through market noise is briefly opening access to his flagship trading strategy. In a short demo, he explains how his “One Ticker” approach works — and how readers can access the full service for a year at a steep discount.Watch the brief demo here

Context matters to understand Novo’s path forward. The company reshaped the weight-loss drug market in 2021 with Wegovy (semaglutide), and the trajectory of its sales growth tells the story of how quickly fortunes shifted.

Novo’s Q3 2025 results are the most recent available report, so we’ll compare year-over-year Q3 sales growth from 2021 through 2025.

Novo’s Q3 Sales Growth by Year

• 2021: 15%
• 2022: 28%
• 2023: 29%
• 2024: 21%
• 2025: 5%

After accelerating through 2023, sales growth collapsed to just 5% in Q3 2025. The critical inflection point came in November 2023, when the FDA approved Eli Lilly and Company’s (NYSE: LLY) weight-loss drug Zepbound (tirzepatide). That approval helped drive Lilly’s total sales growth of 54% in Q3 2025, a stark contrast with Novo’s 5% result.

By February 2025, Lilly had overtaken Novo in U.S. market share for incretin analogs, according to slide 10 of Lilly’s Q3 presentation. “Incretin analogs” is a broad term for GLP-1 and related drugs. Since then, Lilly’s lead has widened, in part because injectable tirzepatide produces roughly 50% greater weight loss than injectable semaglutide. Novo’s newly approved oral option may help the company regain momentum.

NVO’s Pill: Potential First-Mover and Efficacy Advantages Over LLY

Oral weight-loss drugs have become a new battleground between Novo and Lilly. Both companies are targeting patients who prefer to avoid injections; oral formulations can also lower manufacturing costs and improve long-term adherence. Novo’s oral Wegovy gives it several advantages.

First, Novo has a head start: the company expects to begin selling the pill in January 2026. Lilly’s oral candidate, orforglipron, is not yet approved; most analysts expect FDA clearance no earlier than late March 2026. That window could give Novo several months to build share among oral GLP-1 patients.

Efficacy data also favor Novo. Novo’s oral Wegovy showed an average weight loss of 16.6% after 64 weeks in its trial, compared with Lilly’s reported 12.4% average weight loss for orforglipron after 72 weeks in its study (Lilly release).

Adjusting for placebo response and treatment discontinuations narrows the gap—adjusted figures are roughly 11.2% for oral Wegovy versus about 9.1% for orforglipron. Still, oral Wegovy achieved greater weight loss in a shorter time frame, which could encourage both patients and physicians to favor Novo’s pill even after Lilly’s product reaches the market.

What FDA Approval of the Wegovy Pill Changes for 2026

Novo urgently needs a product to reaccelerate growth, and oral Wegovy could be that catalyst. With the stock down sharply in 2025, a solid rebound in 2026 would not be surprising if uptake is strong.

Long-term success, however, depends on continued innovation. One late-stage pipeline candidate, CagriSema, produced average weight loss of 22.7% at 68 weeks and could materially bolster Novo’s position if approved.

Overall, the outlook for Novo shares is tilted to the upside, but oral Wegovy’s sales trajectory in 2026 will be a critical test of the company’s ability to keep pace with Lilly over the longer term.

Thank you for subscribing to Earnings360, a morning newsletter that summarizes quarterly earnings for public companies that trade on U.S. markets.

This email communication is a paid advertisement provided by Weiss Ratings, a third-party advertiser of Earnings360 and MarketBeat. 

11780 US Highway 1,
Palm Beach Gardens, FL 33408-3080
Would you like to edit your e-mail notification preferences or unsubscribe[/link] from our mailing list?

Copyright © 2025 Weiss Ratings. All rights reserved.
 
 
If you need assistance with your newsletter, please email our U.S. based support team at contact@marketbeat.com.

If you no longer wish to receive email from Earnings360, you can unsubscribe.

© 2006-2026 MarketBeat Media, LLC. All rights reserved.
345 N Reid Pl., Suite 620, Sioux Falls, S.D. 57103-7078. United States of America..

See Also: Forget AI, This Will Be the Next Big Tech Breakthrough (From Brownstone Research)

Buying Gifts on Amazon? This Card Could Be Worth…

Buying Gifts on Amazon? This Card Could Be Worth $100sBy The Flash Report • 6 Jan 2026 View in browser

Prime members could unlock a bonus many people may not notice.A welcome bonus valued in the hundreds, issued after approval.No purchase required to get the bonus.No annual fee.Learn how to applyMore like thisLess like thisKEEP READINGThe Lithium BoomDid you know it takes 10,000 iPhone batteries worth of lithium to make one EV battery pack? With 350M+ EVs projected to be sold g…Something special to unwrap this seasonYou have a “no strings attached” offer waiting. Prime members are eligible for a limited-time bonus offer instantly upon approva…Amazon bonus offer worth hundreds if you’re approved.If you have items in your Amazon cart right now, do not click “Place Order” yet. You are potentially missing a generous bonus th…Operated by Inception Media LLC.  901 N Market St Suite #100, Wilmington, DE 19801, United StatesThe Flash Report © 2026 – Unsubscribe

newswiredaily.org

newswiredaily.org

Let’s Get to Work

Hi CUTS Community, Every year gives us a chance to reset, learn, and raise the standard. As we step into 2026, our focus is clear: build better product, operate with intention, and stay closely connected to the people who believe in what we’re building. Tomorrow, we’re kicking off the year with the launch of our Divine Fleece collection. Three complete sets, a quarter zip, and new sweats designed for everyday wear, travel, and the moments in between. This drop represents what we care most about right now: comfort, versatility, and pieces that earn a spot in your weekly rotation. New Products and Constant Core RestocksThis year, we’re getting back to basics and doing them right. Our top priority is maintaining consistent inventory in our core styles. You can expect regular monthly color restocks in the AO Tees, AO Joggers, and Hyperloop styles. Last year, we missed too many months without core restocks. That won’t happen in 2026.Alongside that, we’ll be introducing new collections every month. We’re starting with the Divine Fleece launch tomorrow, followed by an epic Spring Drop in late March. That drop will include restocks of the Riviera Knit and SoHo Trousers + Button Ups, along with several new styles we’ve been excited to bring to life.The goal is simple: always have your go-to essentials available, while continuing to introduce new product that moves the brand forward.Our mission hasn’t changed. CUTS exists to serve those showing up every day in the Sport of Business. People building, grinding, creating, and pushing forward. Everything we release is built with that mindset. Pricing & Value We understand that cash is tight for a lot of people right now. Inflation and rising costs are real, and we don’t take that lightly. While we continue to invest in premium fabrics and top-tier manufacturing, we’re committed to creating ways for you to get more value.This year, you’ll see more bundles across our core styles. The idea is simple: the more you buy, the more you save. Whether you’re restocking essentials or building out a full set, bundles allow us to pass savings directly back to you without cutting corners on quality. Quality First Over the last year, we’ve doubled down on quality. Better fabrics, improved construction, and tighter consistency across fits and finishes. Our newer manufacturing partnerships are helping us raise the bar across every category, and Divine Fleece is a strong example of that progress.This is ongoing work, and we’re committed to continuing to improve with every release. Customer Support We’re continuing to invest in how we show up for you beyond the product. That means clearer communication, faster support, and being more proactive when things don’t go perfectly. Our goal is simple: treat every customer with care and respect, every time. Connecting With You Some of the best moments last year were meeting many of you in person at events and in-store experiences. Those connections matter to us, and we’re planning more opportunities to connect face-to-face in 2026. Thank You None of this happens without your trust and support. We’re grateful for every order, every message, and every person who chooses CUTS. We’re not just building clothing. We’re building something bigger, together. We have a saying around the office, and we turned it into a URL.  Check it out: www.whogonstopme.com “Who Gon’ Stop Me” is about ownership. About resilience. About deciding that obstacles don’t get the final say. It’s a reminder that progress belongs to those willing to keep moving forward. Here’s to a strong start and an even stronger year ahead. Sincerely, Steven Borrelli

Hilton Severs Tie With Minn. ICE Protest Hotel; Trump…

Breaking News from Newsmax.com

• Hilton Removes Minneapolis Hotel From Its System Over Canceled ICE ReservationsSpecial: Thousands Rush to 0% APR Cards Lasting Until Nearly 2028• Trump: Need an ‘Epic Midterm Victory’ or Dems Will Impeach Me• Trump Mocks Paid Pro-Maduro Protesters

SPONSOR

ADVERTORIALThousands Rush to 0% APR Cards Lasting Until Nearly 2028New year, new goals—why let credit card interest hold you back? High APRs keep you stuck, no matter how hard you try.Here’s your fresh start:CardCritics has handpicked balance transfer cards that pause interest for nearly 2 years—so every payment moves you forward.What you’ll love: 🧾 0% intro APR on balance transfers 💰 Massive savings—hundreds or thousands off your debt 🚫💳 $0 annual fees—because progress shouldn’t come with a price tagMake this the year you take control. Check out CardCritics’s top picks today!

This email is never sent unsolicited. You have received this Newsmax email because you subscribed to it or someone forwarded it to you. To opt out, see the links below.Remove your email address from our list or modify your profile. We respect your right to privacy. View our policy. This email was sent by: Newsmax.com 362 N. Haverhill Road West Palm Beach, FL 33415 USA DM903597 010502p82epf

BSEM: Leaving the OTC Behind? Potential Nasdaq Uplisting THIS…

You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. This message is from Huge Alerts.BSEM: SEVEN STRAIGHT PROFITABLE QUARTERS AND A POTENTIAL NASDAQ MOVE IN 2026!Clinically Proven MedTech Disruptor BSEM is Separating from the Pack, Targeting a $300M+ Market, and Has a $25.50 Analyst Price Target!Greetings All,The MedTech sector sits at the intersection of innovation, necessity, and scale—and that combination makes it one of the most powerful long-term investment themes in global markets. Aging populations, rising chronic disease, and relentless healthcare demand mean spending doesn’t slow just because the economy does. Yet within MedTech, only a handful of companies combine real profitability, clinical proof, and expanding market access. BioStem Technologies (OTC: BSEM) is one of them—and as 2026 approaches, it’s a name that should not be ignored.Seven Straight Profitable Quarters in a Sector Where Most Still Burn CashBSEM just delivered another resilient quarter, reporting $10.5 million in Q3 2025 revenue, $0.8 million in GAAP net income, and $2.7 million in adjusted EBITDA—marking its seventh consecutive profitable quarter. In small-cap regenerative medicine, that kind of consistency is rare. Even with pricing pressure and reimbursement shifts, BSEM maintained an 88.5% gross margin and closed the quarter with $27.2 million in cash, reinforcing its ability to fund growth without diluting shareholders. BioREtain® Delivers Level 1 Clinical Proof—Dominates Standard of CareBioStem’s proprietary BioREtain® processing technology is the engine behind its momentum. A published Level 1 randomized controlled trial in diabetic foot ulcers showed a 53% probability of complete wound closure, compared to just 31% with standard of care—a massive clinical advantage in one of healthcare’s most expensive and dangerous chronic conditions. Conducted under FDA-level rigor and published in a peer-reviewed journal, the data validates BSEM’s claim that preserving the natural structure and growth factors of placental tissue leads to better, more durable healing. A $27 Billion Wound-Care Market with Multiple New Growth ChannelsDiabetic foot ulcers alone cost the U.S. healthcare system $9–$13 billion annually, with millions of patients at risk of infection, hospitalization, and amputation. BioStem is expanding aggressively into high-value channels, including the Department of Veteran Affairs, state Medicaid programs like Texas, hospitals, and ambulatory surgery centers. These initiatives open the door to a $300–$350 million addressable market, with broader federal and state access planned for 2026. Volume is already telling the story—product units sold jumped 40% year over year, even in a challenging pricing environment.Nasdaq Uplisting Could Be the Visibility ShockwaveBSEM is actively targeting a Nasdaq uplisting in mid-2026, following completion of KPMG audits and renewed SEC engagement. An uplisting would dramatically increase liquidity, unlock institutional ownership, and re-rate the stock alongside listed MedTech peers. With FDA-registered, AATB-accredited manufacturing, a growing patent portfolio, and national reimbursement coverage, BSEM is building the exact profile institutions look for—but hasn’t fully priced in yet.$25.50 Zacks Target Signals Significant Upside PotentialZacks Small Cap Research has placed a $25.50 price target on BSEM, reflecting confidence in its profitability, clinical validation, and expanding footprint. While reimbursement reform and pricing pressure remain short-term risks, management believes those same reforms will favor technologies that deliver proven outcomes and economic value—exactly where BioStem excels. THE BOTTOM LINEBioStem Technologies is no longer a speculative MedTech story—it’s a profitable, clinically validated growth company with expanding market access and a clear path toward greater visibility. Seven straight profitable quarters, breakthrough clinical data, new federal and state channels, and a potential Nasdaq uplisting make BSEM one of the most compelling MedTech names to watch in 2026. Start your research! We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security.We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of BioStem Technologies Inc. (OTC: BSEM) . The compensation consists of up to $6,500 and was received/will be received from Sideways Frequency.This compensation should not be considered as an endorsement of the securities of BioStem Technologies Inc. (OTC: BSEM) and we are not responsible for any errors or omissions in any information provided about the securities of BioStem Technologies Inc. (OTC: BSEM) by Huge Alerts.We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions.This disclosure is made as of 01/06/2026.Our mailing address is:  Behind the Markets, LLC  4260 NW 1st Avenue, Suite 55  Boca Raton, FL 33431 Copyright © 2024 Behind the Markets, LLC, All rights reserved.  You’re receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices. Behind the Markets You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. Today’s Bonus Content: Flu Season Stocks Are on Sale

Big News: Music in the Mountains May 2026

VIEW THIS EMAIL IN BROWSER LW Updates January 6, 2026  INSTAGRAM TWITTER FACEBOOK Copyright (C) 2026 Lindsey Webster. All rights reserved. You are receiving this email because you signed up for notifications on my website: www.lindseywebstermusic.com! Our mailing address is: Lindsey Webster Box 11 Woodstock, NY 12498 USA Want to change how you receive these emails?You can update your preferences or unsubscribe

BREAKING: SpaceX Wants Apple’s Secret Partner?

AN OXFORD CLUB PUBLICATION

Loyal reader since August 2025

THE SHORTEST WAY TO A RICH LIFEBREAKING: SpaceX Wants Apple’s Secret Partner? Nicole Labra, Senior Managing Editor, The Oxford Club Dear Reader,Something massive has developed since we first released our Apple presentation.I’m hearing that SpaceX – yes, Elon Musk’s SpaceX – is quietly in talks to acquire the same tiny company Apple has been secretly partnering with.Think about what this means…Two of the world’s most innovative companies are now interested in the same stock.Apple has already invested $1.5 billion and owns 20% of this company.Now SpaceX wants it too.Why?Because this small company owns something that CANNOT be bought anywhere else.When Wall Street realizes that both Apple AND SpaceX are interested in this tiny company…When CNBC starts talking about it…The share price won’t just rise. It could absolutely explode higher.That’s why I’m urging you – no, I’m WARNING you – watch our presentation about this opportunity right now.Not tomorrow… NOW.Because once this SpaceX news breaks wide open, the opportunity to get in early could be gone forever.[Click here to discover Apple’s Secret Partner before the rest of the world does]Sincerely,NicoleP.S. Alexander Green says this company is 800 times smaller than Apple. If SpaceX acquisition talks are real, this stock could skyrocket overnight. [Get the full breakdown here – time is running out.]  You are receiving this email because you subscribed to Liberty Through Wealth. Liberty Through Wealth is published by The Oxford Club. To stop receiving special invitations and offers from Liberty Through Wealth, please click here. Please note: This will not impact the fulfillment of your subscription in any way.Questions? Check out our FAQs. Trying to reach us? Contact us here. Please do not reply to this email as it goes to an unmonitored inbox. Privacy Policy | Whitelist Liberty Through Wealth © 2026 The Oxford Club, LLC All Rights Reserved The Oxford Club | 105 West Monument Street | Baltimore, MD 21201 North America: 866.237.0436 | International: 443.353.4540 Oxfordclub.com  Nothing published by The Oxford Club should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by The Oxford Club should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The Oxford Club, LLC, 105 West Monument Street, Baltimore, MD 21201.REF: 000142349377

Peter, register now for our webcast | The Implications…

The Implications of U.S. Intervention in VenezuelaThe U.S. capture of Nicolas Maduro in Venezuela and the announcement of temporary U.S. control over the country have triggered significant global attention. While the revitalization of Venezuela’s oil industry is a stated goal, the immediate market response has been muted, as expected. However, these developments raise several important questions:1.How might these actions impact the role of the U.S. on the global political stage in an increasingly fragmented world?2.Could a leadership change in Venezuela lead to greater oil production from the country with the world’s largest reserves, and what might this mean for global energy markets in both the near and long term?3.What are the potential implications for the region, in a year in which both Colombia and Brazil face presidential elections? How could these events shape the future of optionality for Latin America?Please join Derek Chollet, Nur Cristiani, Clay Erwin and Stephen Jury as our team explores what may be next for Latin America, Venezuela and the broader global geopolitical landscape.

CONTINUE

Join us for this eventDate: Wednesday, January 7, 2026Time: 11:00 a.m. EST

Our Speakers

Derek CholletHead of the JPMorganChase Center for Geopolitics J.P. MorganNur CristianiHead of LATAM Investment Strategy J.P. Morgan

Stephen JuryGlobal Commodity Strategist J.P. MorganClay ErwinGlobal Head of Investment Sales & Training J.P. Morgan

CONTINUE

UNLOCK YOUR ACCESS TO INSIGHTS FROM OUR INDUSTRY LEADERSAccess our on-demand webcast library for the latest market commentary and gain valuable insights from industry leaders.EXPLORE NOW

Email Security InformationEmail intended for: pahovis@aol.com If you have concerns about the authenticity of this message, please visit chase.com/CustomerService for options on how to contact us.Important Information‌ The views, opinions and estimates expressed herein are those of the speakers and are subject to change without notice. Opinions herein may differ from those expressed by other areas of J.P. Morgan Wealth Management. This information in no way constitutes J.P. Morgan Research and should not be treated as such. The views contained herein are not to be taken as an advice or a recommendation to buy or sell any investment in any jurisdiction and there is no guarantee that any of the views expressed will materialize. Any forecasts, figures, opinions or investment techniques and strategies set out are for information purposes only; based on certain assumptions, current market conditions and are subject to change without prior notice. All information presented herein is considered to be accurate at the time of writing, but no warranty of accuracy is given and no liability in respect of any error or omission is accepted. This material does not contain sufficient information to support an investment decision and it should not be relied upon by you in evaluating the merits of investing in any securities or products. In addition, investors should make an independent assessment of the legal, regulatory, tax, credit, and accounting implications and determine, together with their own professional advisers, if any investment mentioned herein is believed to be suitable to their personal goals. Investors should ensure that they obtain all available relevant information before making any investment. It should be noted that investment involves risks, the value of investments and the income from them may fluctuate in accordance with market conditions and investors may not get back the full amount invested. Both past performance and yield may not be a reliable guide to future performance.‌ Closed captions are made available for all J.P. Morgan Wealth Management webcast events. If any accommodation is needed for this event (for example, ASL interpretation), please contact: jpmwm.events@jpmorgan.com‌ JPMorgan Chase & Co. and its affiliates do not provide tax, legal or accounting advice. This material has been prepared for informational purposes only, and is not intended to provide, and should not be relied on for tax, legal or accounting advice. You should consult your personal tax, legal and accounting advisors for advice before engaging in any transaction.‌ Asset allocation/diversification does not guarantee a profit or protect against a loss.‌ J.P. Morgan Wealth Management is a business of JPMorgan Chase & Co., which offers investment products and services through J.P. Morgan Securities LLC (JPMS), a registered broker-dealer and investment adviser, member FINRA and SIPC. Insurance products are made available through Chase Insurance Agency, Inc. (CIA), a licensed insurance agency, doing business as Chase Insurance Agency Services, Inc. in Florida. Certain custody and other services are provided by JPMorgan Chase Bank, N.A. (JPMCB). JPMS, CIA and JPMCB are affiliated companies under the common control of JPMorgan Chase & Co. Products not available in all states.INVESTMENT AND INSURANCE PRODUCTS: • NOT A DEPOSIT • NOT FDIC INSURED • NOT INSURED BY ANY FEDERAL GOVERNMENT AGENCY • NO BANK GUARANTEE • MAY LOSE VALUEABOUT THIS MESSAGE This service email gives you updates and information about your J.P. Morgan relationship. This email was sent from an unmonitored mailbox. Go to chase.com/CustomerServicefor options on how to contact us. ‌ Your privacy is important to us. See our online Security Center to learn how to protect your information. ©2026 JPMorgan Chase & Co. ‌ LC-JANSDIPB126